|
|
||||||||
E(CD103)
7 Mediates Adhesion to Intestinal Microvascular Endothelial Cell Lines Via an E-Cadherin-Independent Interaction1


*
The Lymphocyte Biology Section, Division of Rheumatology, Immunology, and Allergy, and
Pulmonary and Critical Care Division, Brigham and Womens Hospital, Boston, MA 02115; and
Medical College of Wisconsin, Milwaukee, WI 53226
| Abstract |
|---|
|
|
|---|
E
7 is
expressed on some circulating gut-homing T cells and as T cell numbers
are reduced in the intestinal lamina propria of
E-deficient mice, we evaluated whether
E
7 mediates binding to intestinal
endothelial cells. We found that
anti-
E
7 mAbs partially blocked the
binding of cultured intraepithelial T cells to human intestinal
microvascular endothelial cells (HIMEC). Furthermore,
E
7-transfected K562 cells bound more
efficiently than vector-transfected K562 cells to HIMEC. Finally, HIMEC
bound directly to an
E
7-Fc fusion
protein. These interactions were partially blocked by
anti-
E
7 mAbs, and endothelial cell
binding to the
E
7-Fc was dependent upon
the metal ion-dependent adhesion site within the
E A
domain. Of note, the HIMEC lacked expression of E-cadherin, the only
known
E
7 counterreceptor as assessed by
functional studies, flow cytometry, and RT-PCR. Thus,
HIMEC/
E
7 binding was independent of
E-cadherin. In addition, this interaction appeared to be tissue
selective, as HIMEC bound to the
E
7-Fc,
whereas microvascular endothelial cells from the skin did not. Finally,
there was evidence for an
E
7 ligand on
intestinal endothelial cells in vivo, as
E
7 expression enhanced lymphocyte binding
around vessels in the lamina propria in tissue sections. Thus, we have
defined a novel interaction for
E
7 at a
nonepithelial location. These studies suggest a role for
E
7 in interactions with the intestinal
endothelium that may have implications for intestinal T cell homing or
functional responses. | Introduction |
|---|
|
|
|---|
The mechanisms of T lymphocyte extravasation and localization within
the intestinal lamina propria appear to involve processes similar to
those described above, although the specific molecules that are
critical for each step differ (1). In particular, the
7 integrin subfamily, including
4
7 and
E
7, are important in
T cell homing to and localization in the intestine (1, 5).
Integrin
4
7 is
expressed at high levels on a small subset of circulating memory T
cells (6, 7) that selectively localize to the Peyers
patches and to the intestinal lamina propria (1). In
addition, it is found on
70% of lamina propria T lymphocytes but on
only a minority of intestinal intraepithelial lymphocytes
(iIEL)3
(8). Integrin
4
7 binds to mucosal
addressin cell adhesion molecule-1 (MAdCAM-1), a molecule expressed
selectively on intestinal endothelial cells that mediates T cell
interactions with intestinal vessels (9, 10, 11, 12). This
interaction appears to be important for T cell homing to the lamina
propria as intestinal T cell numbers are reduced in
7 integrin-deficient mice (5). In
addition, mAbs that recognize
4
7 or MAdCAM-1
inhibit lymphocyte migration into Peyers patches and the lamina
propria (13), and inhibit the generation of intestinal
inflammation in murine models (14, 15).
Overall, there appears to be a correlation between the distribution of
an adhesion molecule on the cell surface and its capacity to mediate
rolling on endothelia. Molecules that have the capacity to mediate
rolling on endothelia, such as L-selectin, are displayed on the
microvillus tips protruding from the surface of the cells (16, 17). Furthermore, molecules expressed on microvillus tips are
especially able to mediate rolling under conditions of flow (18, 19). Consistent with the finding that
4
7 is expressed on
the microvillus tips of
4
7-transfected K562
cells (17), it mediates rolling of lymphocytes on
endothelia (9, 20). In addition,
4
7 can mediate the
stronger interaction that is typical of an integrin after
chemokine-induced activation (20). Thus, it is apparent
that integrin
4
7 is
important for lymphocyte trafficking to the intestinal mucosa. Its role
in T cell retention with the lamina propria or in the intestinal
epithelium is not known.
The only other known
7 integrin is
E
7. It is expressed
on a subset of the circulating
4
7high
memory CD8+ T cells, approximately two-thirds of
which coexpress the C-C chemokine receptor 9, which is selectively
expressed on gut-homing T cells (21). Integrin
E
7 also is expressed
on >90% of CD8+ and
40% of
CD4+ lamina propria T cells and iIEL
(22, 23, 24). The
E
7 integrin mediates
T cell adhesion to epithelial cells via its interaction with epithelial
cadherin (E-cadherin; Refs. 25, 26, 27, 28), leading to the
suggestion that
E
7 is
involved in iIEL retention. In support of a role of
E
7 in T cell binding
to epithelial cells,
E
7 is expressed on
epidermotropic lymphomas (29, 30, 31). In addition, a recent
report has suggested that
E
7 mediates
lymphocyte binding to a skin-derived epithelial cell line through an
E-cadherin-independent interaction (32).
Whether the
E
7
integrin is also involved in T cell extravasation into the lamina
propria has not been resolved. Of note, splenocytes induced to express
E
7 after culture with
TGF-
1 do not localize preferentially to the
intestine (33). Furthermore,
E
deficiency does not modulate the localization of OVA-specific
CD8+-transgenic T cells to the intestinal
epithelium after adoptive transfer and systemic T cell activation
(34). However, like
4
7 and other
molecules that can mediate leukocyte rolling on endothelial cells,
E
7 is expressed on
the microvillus tips of
E
7-transfected K562
cells (17). In addition, lamina propria T cell numbers are
reduced in
E-/- mice to
only 50% of that observed in
E+/+ mice (35),
whereas lamina propria T cell numbers are normal in mice whose T cells
lack
4 expression (36). Thus,
although
4
7 is
critical in T cell localization to Peyers patches, another
7 integrin appears to mediate T cell
extravasation within the intestinal mucosa. These findings would be
consistent with a possible role of
E
7 in gut-homing T
cell interactions with the intestinal endothelium, and led us to
evaluate whether such endothelial cells express an
E
7 ligand.
| Materials and Methods |
|---|
|
|
|---|
mAbs used included anti E-cadherin (E4.6, Ref. 26 ;
and HECD-1; Zymed, San Francisco, CA), anti-
E (
E7-1 (28C12),
E7-2 (26F1),
E7-3 (2G9; Ref. 24)), and BerACT-8
(37), anti-
1 (4B4; Ref. 38),
anti-
7 (Fib504; American Type Culture
Collection (ATCC), Manassas, VA),
anti-
4
7 (ACT-1;
Ref. 39), anti-LFA-1 (D6.21; Ref. 25),
anti-MHC class I (W6/32; ATCC), anti-vascular endothelial
cadherin (anti-VE-cadherin; PharMingen, San Diego, CA),
noncell-binding control IgG1 (P3; ATCC), and anti-human Fc (Zymed).
Purified human IgG1 was obtained from Calbiochem (San Diego, CA).
E- and
7-transfected
K562 cells, the E-cadherin-Fc-producing 293 cell line, human IEL lines,
the
E-transfected human B lymphoblastoid cell
line JY'-
E, and the human breast epithelial cell line MCF-7 were
grown as described (17, 28, 40). Human intestinal
microvascular endothelial cell (HIMEC) lines were isolated and grown as
characterized previously (41). Human microvascular
endothelial cells (HMVEC) were obtained from Clonetics (Walkersville,
MD) and cultured according to the suppliers instructions. Endothelial
cells were not used beyond passage 7.
Production of soluble recombinant
E
7-Fc fusion protein
To generate an
E-Fc construct, a
fragment of the
E-cDNA encoding for the entire
extracellular domain (nucleotides 126-3496, GenBank Accession no.
NM_002208) was ligated to the hinge and Fc region of human IgG1 as
described for human E-cadherin-Fc (28), incorporating a
linker encoding for the peptide sequence Ala-Ser-Gly-Gly-Gly-Leu-Glu
between the integrin and Fc domain to confer flexibility. The construct
was ligated into the pCEP4 expression vector (Invitrogen, Carlsbad,
CA). The
7-Fc fusion protein, incorporating
nucleotides 151-2323 (GenBank Accession no. NM_000889), was generated
similarly. The constructs were cotransfected into human embryonic
kidney (HEK)-293 cells by calcium phosphate precipitation
(42), and the transfected cell line was cloned by limiting
dilution. Clones producing the greatest quantity of soluble heterodimer
were identified based on sandwich ELISA of the supernatant
(43) using the anti-
7 mAb
Fib504 for capture and the biotinylated
anti-
E mAb
E7-1 for detection. For
biochemical analysis, 20 ml of supernatant was passed over a 300-µl
protein G column, and the adsorbed protein was analyzed by SDS-PAGE
followed by Coomassie blue staining as described previously (predicted
Mr: 
-Fc = 280 kDa,
-Fc = 160 kDa,
-Fc = 120 kDa, 
-Fc = 320 kDa,

-Fc = 240 kDa) (44). A soluble
E construct containing a mutation in the metal
ion-dependent adhesion site (MIDAS) was generated by exchanging
fragment 236-1256 of the
E-Fc with a similar
fragment from the full-length
E(D190A) subunit
(44) using BpuII02I sites. Cotransfection and subcloning
of
E(D190A)
7-Fc was
performed as described for
E
7-Fc.
Adhesion assays
Static cell-cell adhesion assays were conducted in 96-well
tissue culture plates as previously described (25), with
the modification that labeled cells were incubated on confluent HIMEC
monolayers for 30 min at 37°C. Nonadherent cells were removed by
inverting the plate in HEPES-buffered saline/50 mM dextrose/1 mM
Ca2+/Mg2+/Mn2+
for 30 min and subsequently flicking the inverted plate. For
cell-fusion protein adhesion assays, ELISA plates were coated with goat
anti-human Fc mAb as described (28) and incubated for
1418 h at 4°C with 100 µl/well of undiluted supernatant from
HEK-293 cells producing high levels of
E
7-Fc (
100
ng/well). In parallel, adherent cells were released from the tissue
culture flask using 0.02% trypsin/HEPES-buffered saline/2 mM
Ca2+. After fluorescence labeling, 3 x
104 cells were added to each well, and the
adhesion assay was performed in the presence of 1 mM
Ca2+/Mg2+/Mn2+
as described (28), unless otherwise indicated. For mAb
blocking experiments, cells were incubated with 20 µg/ml of purified
Ab for 15 min on ice before performing the assay. The concentration of
E
7-Fc and of
E(D190A)
7-Fc in
culture supernatants were estimated to be 1 and 0.8 µg/ml,
respectively, based upon anti-Fc-based ELISA. For adhesion assays
comparing HIMEC binding to both fusion proteins, the
E
7-Fc containing
supernatant was diluted to 0.8 µg/ml before use.
PCR assay
For PCR, 3 x 106 MCF-7 cells and a
similar number of HIMEC were harvested using cells from a culture
passage at which they were known to bind to the
E
7-Fc in adhesion
assays. Then, mRNA was prepared using the QuickPrep Micro mRNA
purification Kit (Pharmacia Biotech, Uppsala, Sweden). After DNAaseI
digestion, cDNA synthesis was initiated using a cDNA Synthesis Kit
(Clontech, Palo Alto, CA). PCR was performed using G3PDH primers
(Clontech) and the primer pair E-cad-5'
(5'-aagagagactgggttattcctcccatc-3') and E-cad-3'
(5'-gccatcgttgttcactggatttgt-3') encoding for a 848-bp piece of the
N-terminal region of E-cadherin, spanning 6 introns, which include a
total of 166 bp. The PCR conditions for E-cadherin detection were
94°C for 3 min followed by 40 cycles of 94°C for 1 min, 60°C for
1 min, and 72°C for 2 min.
Flow cytometry analysis
FACS analysis was performed as previously described (24) using the FACScan flow cytometer (Becton Dickinson, Mountain View, CA) and CellQuest software (Becton Dickinson).
Stamper-Woodruff assays
A modified Stamper-Woodruff assay was performed to assess cell
binding to lamina propria (45). BCECF labeled JY'-
E
(which express
E
7 due
to the presence of an endogenous
7 subunit) or
JY'-v cells were incubated in RPMI 1640 medium on 10-µm cryosections
of human proximal small intestine under static conditions for 30 min at
37°C. Then, nonadherent cells were removed by dipping the slides in
PBS, and the tissue was fixed with 7% formalin/PBS. The number of
bound cells per 0.5-mm villus length was determined via visual
inspection by a observer, blinded to the cell source, using a
fluorescence microscope (Nikon, model UFX-DX; Tokyo, Japan, objective).
For colocalization experiments, IEL lines were used because of their
high level of
E
7 cell
surface expression. Tissue sections were preincubated with 10 µg/ml
of the endothelial cell-specific anti-VE-cadherin mAb for 45 min,
followed by 1:150 Texas Red-conjugated goat anti-mouse (Jackson
ImmunoResearch, West Grove, PA) and washed in HEPES-buffered saline.
Thus, BCECF-labeled IEL, after incubation with 20 µg of the
anti-
E mAb
E7-1 or control-mAb (W6/32),
were added to the tissue sections in HEPES-buffered saline containing 1
mM Ca2+, Mg2+, and
Mn2+. The assay was subsequently performed as
described above. Of note, the green labeling of IEL was visible under
all powers of magnification. However, the red labeling of endothelial
cells was only visible in the high power views. Cells were counted per
0.1-mm villus length by an unblinded observer.
| Results |
|---|
|
|
|---|
E
7 mAbs partially block the
binding of iIEL lines to HIMEC
To determine whether
E
7 mediates binding
of T lymphocytes to HIMEC, the 486 IEL-derived T cell line was used.
Approximately 80% of the cells in this line constitutively expressed
E
7 at moderate to
high levels (mean fluorescence intensity (MFI) = 150). In two of
three experiments performed,
35% of the IEL line bound to a HIMEC
monolayer. When adhesion above background was considered, three
different anti-
E
7
mAbs blocked the IEL/HIMEC binding significantly, by
3540%, and a
fourth mAb blocked more modestly (Fig. 1
). In contrast, the IEL/HIMEC
interaction was blocked only marginally by an
anti-
4
7 mAb and
was not blocked by isotype-matched mAbs specific for MHC-I, E-cadherin,
or
L
2. Of note, the
486 IEL line expressed
4
7 at only modest
levels (MFI
30), that may not be sufficient for assessing adhesion
in these assays. These studies suggested that
E
7+
IEL bind to HIMEC in a static adhesion assay, in combination with other
interactions that have not been defined.
|
E
7 bind to HIMEC
To confirm that
E
7 expression confers
cell binding to HIMEC, static cell-cell adhesion assays were performed
using
E
7-transfected
K562 cells (17). These cells constitutively expressed
moderate levels of
E
7
(MFI
150). In the experiments shown, 11.8 or 12.9% of the
K562-
E
7 cells bound
to a confluent layer of HIMEC, as compared with only 4.2 or 5.1% of
vector-transfected K562-v cells, respectively (Fig. 2
). Three different
anti-
E mAbs and one
anti-
7 mAb blocked the adhesion of
K562-
E
7 cells to
HIMEC, almost to the level of adhesion seen with K562-v cells (Fig. 2
).
In contrast, K562-
E
7
adhesion to HIMEC was not blocked by isotype-matched cell-binding
control mAbs (anti-MHC I,
anti-
L
2) or by an
anti-E-cadherin mAb that is known to block the binding of
E-cadherin to
E
7
(26, 28) (Fig. 2
B). The difference between
vector- and
E
7-tranfected K562
cell binding was highly reproducible in multiple independent assays
using HIMEC isolated from five different donors and two independently
derived K562-
E
7
lines. In the ten assays performed, on average 15.6% ±3.04
of K562-
E
7 cells
adhered to HIMEC as compared with 4.41% ± 1.68 using
vector-transfected cells (p = 0.0001,
Mann-Whitney U test).
|
E
7-Fc fusion protein
The analysis of cell-cell adhesion assays is complicated by
possible interactions of multiple adhesion receptors. Also,
anti-integrin mAbs can trigger intracellular signals that may
modify the functions of other molecules. Thus, although suggestive, the
cell-cell adhesion assays described above did not definitively
demonstrate that
K562-
E
7 binding to
HIMEC was
E
7
mediated. To establish an
E
7-specific adhesion
assay system, a pair of
E- and
7-Fc fusion protein encoding constructs was
generated (Fig. 3
A) and
transfected stably into HEK-293 cells. Based upon SDS-PAGE analysis,
the size of the predominant secreted protein was consistent with the
predicted size of a disulfide-linked
E
7 heterodimer, as it
migrated with an Mr of 270 kDa under
nonreducing conditions and 120 and 160 kDa under reducing conditions.
In addition, weaker bands were observed at
300 and 230 kDa under
nonreducing conditions, suggesting the generation of lesser amounts of

and 
homodimers, respectively (Fig. 3
B). The
E
7-Fc fusion protein
was not stable to purification using a protein G column and elution at
low pH. However, due to the presence of human IgG1-Fc it was captured
onto wells with an anti-Fc Ab for use in adhesion assays.
|
E
7-Fc was functional,
we evaluated its ability to bind to E-cadherin-expressing cells.
E-cadherin+ MCF-7 cells adhered with equal
efficiency to
E
7-Fc-
or E-cadherin-Fc-coated wells, but not to wells coated with human IgG1.
Furthermore, adhesion of MCF-7 cells to
E
7-Fc-coated wells
was inhibited by 7085% by two different anti-
E mAbs and by
the anti E-cadherin mAb E4.6 but not by the anti-E-cadherin mAb
HECD-1 that is known to block homophilic E-cadherin binding
(46). In contrast, the homophilic binding of MCF-7 cells
to an E-cadherin-Fc was blocked by HECD-1 but not by E4.6 or the
anti-
E
7 mAbs
(Fig. 3
E
7-Fc-coated
plates through an
E
7/E-cadherin based
interaction, confirming that the recombinant integrin fusion protein
was functional.
HIMEC bind to the
E
7-Fe
In additional adhesion assays, >30% of labeled HIMEC bound to
E
7-Fc-coated plates
(Fig. 4
A). Optimal HIMEC
binding was observed with 1 mM
Mn2+/Mg2+/Ca2+
(Fig. 4
A) or with 5 mM Mg2+ (data not
shown), whereas the cells bound only weakly in the presence of 1 mM
Ca2+ or 1 mM Mg2+ when
Mn2+ was absent (data not shown). This pattern of
cation dependence is similar to that observed for interactions of other
integrins with their ligands (47), including
E
7 binding to
E-cadherin (28). Binding of HIMEC to
E
7-Fc-coated plates
appeared to involve the
E
7 portion of the
fusion protein, as HIMEC did not bind to the IgG1 or to an
E-cadherin-Fc fusion protein in which the human IgG1-Fc was
incorporated. Furthermore, the binding was completely blocked by two
distinct anti-
E mAbs and by the
7 mAb
Fib504 (Fig. 4
A). Thus, HIMEC bound to an
E
7-Ig Fc fusion
protein through an
E
7-dependent
interaction.
|
E MIDAS is important in
E
/HIMEC interactions
To further evaluate the specificity of the interaction between the
E
7-Fc and HIMEC, we
generated an integrin fusion protein with a D190A mutation. This
mutation results in loss of function of the MIDAS, a structural binding
site crucial for integrin A domain-ligand interactions
(48), based upon the observation that transfected cells
expressing full-length
E(D190A)
7 do not bind
to E-cadherin-Fc fusion protein-coated plates (45). Thus
the
E A-domain MIDAS is critical for the
E
7/E-cadherin
interaction. HIMEC also failed to bind to the
E(D190A)
7-Fc (Fig. 4
B), confirming that the MIDAS within the
E A domain was critical for this interaction.
In addition, multiple anti-
E mAbs whose
binding sites are mapped to a region close to the MIDAS motif
(44) blocked both
E-cadherin/
E
7 and
HIMEC/
E
7 adhesion
(data not shown). Thus,
E
7 likely uses a
similar region within its A domain both for binding to E-cadherin and
to the ligand on HIMEC.
HIMEC do not bind to
E
7 through an
E-cadherin-based interaction
E-cadherin is the only known ligand for
E
7. Thus, studies
were performed to evaluate whether HIMEC binding to
E
7 was E-cadherin
mediated. Although
anti-
E
7 mAb
blocked adhesion, the anti-E-cadherin mAb E4.6 did not block the
HIMEC/
E
7 interaction
(Figs. 2
B and 4A). As this mAb is known to block
E-cadherin+ MCF-7 binding to
E
7-Fc-coated plates
(Fig. 3
C), this finding suggested that the HIMEC do not bind
to
E
7 via E-cadherin.
In support of this view, HIMEC did not adhere to E-cadherin-Fc fusion
protein-coated plates (Fig. 4
A), demonstrating that there
was not sufficient E-cadherin on the HIMEC cell surface to mediate
E-cadherin/E-cadherin interactions.
To confirm that HIMEC do not express E-cadherin, flow cytometry and PCR
were used. Flow cytometry was performed using two mAbs, E4.6 and
HECD-1, that recognize independent epitopes of E-cadherin. Both mAbs
detected E-cadherin on the cell surface of the epithelial cell line
MCF-7 but did not stain HIMEC, indicating that there was no detectable
cell surface expression level of E-cadherin on the endothelial cells.
In contrast, HIMEC were readily stained with a mAb that recognizes the
endothelial cell-specific molecule VE-cadherin (Fig. 5
A). Finally, mRNA was
prepared from MCF-7 cells and from HIMEC in tandem, and RT-PCR was
performed using E-cadherin-specific primers. In this analysis,
E-cadherin mRNA was readily detected in MCF-7 cells, but was not
observed or was seen only weakly using cDNA derived from HIMEC that
were known to bind to
E
7-Fc in the adhesion
assay (Fig. 5
B). Taken together, these findings indicate
that the binding of HIMEC to
E
7-Fc is mediated via
an E-cadherin-independent interaction.
|
E
7-Fc fusion protein
To assess whether
E
7-Fc binding was
specific to endothelial cells derived from the intestine, the binding
of HIMEC to the
E
7-Fc
was compared with the binding of a microvascular endothelial cell line
derived from human skin (HMVEC). Although HMVEC bound efficiently to
fibronectin, in contrast to HIMEC they did not bind to the
E
7-Fc fusion protein
(Fig. 4
C). To evaluate whether there were known cell
adhesion molecules expressed differently on HIMEC and HMVEC that might
account for this differential adhesion, flow cytometry was performed.
Both HIMEC and HMVEC lacked detectable expression of E-cadherin,
MAdCAM-1, VCAM-1, or E-selectin, and expressed similar levels of
PECAM-1, VE-cadherin, CD34,
1-integrins, and
MHC class I (data not shown). The only difference in cell surface
adhesion molecule expression between these lines was the expression of
low levels of ICAM-1 on HMVEC, which was not observed on HIMEC. These
findings are consistent with previous data demonstrating that
E
7 does not bind to
VCAM-1, ICAM-1, or MAdCAM-1 (10) and suggest that
E
7 binds to
intestinal endothelial cells via a ligand that is distinct from the
previously characterized integrin counterreceptors on endothelial
cells.
E
7 expression enhances cell
binding to lamina propria tissue
To further evaluate whether
E
7 may mediate
lymphocyte adhesion within the lamina propria, modified
Stamper-Woodruff assays were performed (45). For these
assays, JY'-
E cells were used because they are smaller than K562
cells, which made it possible to evaluate their site of binding within
tissue sections. JY'-
E cells bound more
efficiently to the lamina propria in human intestinal tissue sections
than mock-transfected JY'-v cells, suggesting that
E
7 expression on JY'
cells conferred their binding to the lamina propria (Fig. 6
).
|
E
7-expressing cells
bound to endothelial cells, the adherent
E
7+
cells localized primarily along the margin of the lamina propria, in
the region where lamina propria vessels are found (data not shown). To
investigate whether
E
7+
cells bound to endothelial cells, two-color immunohistochemistry was
performed. In these assays, IEL, which express higher levels of
E
7 than the JY'-
E
cells, were labeled in green and used for Stamper-Woodruff assays on
sections in which endothelial cells were stained with
anti-VE-cadherin in red (Fig. 7
E
7 mAb (Fig. 7
E
7 mAb
blocked overall binding to the lamina propria by only 38%, but blocked
binding to lamina propria vessels by 64%, suggesting that the
anti-
E
7 mAb
preferentially blocked IEL binding to intestinal lamina propria
vessels.
|
| Discussion |
|---|
|
|
|---|
E
7 binds to a
counterreceptor expressed on microvascular endothelial cells derived
from the intestine. Specifically, we found that HIMEC bound to
E
7+
cells and to an
E
7-Fc
fusion protein, and that these interactions were blocked by
anti-
E
7 mAbs.
This adhesion required an intact
E A-domain MIDAS, similar to
findings with other integrin
-chains that contain A-domains,
including the interaction of
E
7 with E-cadherin.
However, a mAb that blocks E-cadherin-mediated cell binding to
E
7 did not block
binding of HIMEC to the
E
7-Fc, and HIMEC did
not express detectable levels of E-cadherin, as assess by flow
cytometry and by semiquantitative RT-PCR. Thus, these studies indicated
that the interaction of
E
7/HIMEC was
E-cadherin independent.
In considering the possible role of
E
7 in intestinal T
cell localization, several issues are relevant. First,
E
7 is expressed on a
small population of circulating, memory CD8+ T
lymphocytes. These cells coexpress CCR9, a chemokine receptor that has
been found to be selectively expressed on gut-homing T cells in the
circulation (21, 49). In addition,
E
7 is expressed on
the microvillus tips of
E- and
7-transfected K562 cells (17).
These findings suggest a role of
E
7 in a rolling
interaction within the endothelium, which would be consistent with the
observation that the
E
7/HIMEC interaction
was relatively weak. It also is possible that
E
7 could mediate firm
adhesion of T cells to the endothelium under appropriate conditions of
stimulation, as the function of
E
7 is known to be
regulated by inside-out signals (28).
A possible function of
E
7 in T cell
interactions with the lamina propria endothelium would be consistent
with the previous observation that
E-deficient
mice have diminished numbers of T cells in the lamina propria
(35). However, it is notable that splenic T cells induced
to express
E
7 do not
home to the intestinal mucosa (33). In addition,
E
7 did not play a
role in the localization of transgenic, class I-restricted T cells to
the epithelium following systemic activation (34). Thus,
it is clear that
E
7
expression is not essential for T cell homing to the intestinal mucosa,
nor is it sufficient for this process. However, T cell homing might
involve
E
7/intestinal
endothelial cell interactions in the context of other factors or
conditions, which might include the selective expression of chemokine
receptors on certain lymphocytes subpopulations, and/or the variable
expression of the
E
7
ligand or a chemokine by lamina propria endothelial cells.
The adhesion of
E
7
transfectants to HIMEC was weak, raising question as to the
significance of the interaction. However, the interaction was highly
reproducible using five different HIMEC lines, two independent
E
7-transfected cells
lines, and the binding of IEL to HIMEC was partially blocked by
anti-
E
7 mAbs.
Finally, the Stamper-Woodruff assays support the view that
E
7 mediates binding
of T cells to the intestinal lamina propria endothelial cells in
tissues, possibly indicating that these findings are physiologically
relevant. Many weak molecular interactions, as assessed in an adhesion
assay, can be highly significant in terms of cellular function, such as
selectins binding to their glycosylated ligands (50). In
addition, the
E
7/HIMEC binding
could be important for signal transduction that might alter endothelial
cell and/or T cell phenotype, adhesion, or function. Indeed, some
endothelial cell surface molecules that are important in adhesion also
transduce signals to the endothelial cells, including ICAM-1, PECAM-1,
and L-selectin (51, 52, 53, 54), and integrins are known to
transduce signals within leukocytes (55). Finally, it is
possible that the weak adhesion observed in these assays indicate that
there are only low levels of the
E
7 ligand expressed
on the primary HIMEC in culture, but that but these levels might be
up-regulated by inflammatory or other cytokines. Regulated expression
is a characteristic of other integrin ligands expressed on endothelial
cells, including ICAM-1, an
L
2 ligand; VCAM-1, an
4
1 ligand
(54); and MAd-CAM-1, an
4
7 ligand (56, 57). Studies are underway to further characterize the integrin
E
7 counterreceptor
expressed on intestinal endothelial cells. Once the identity of this
molecule is defined at the molecular level, it will be possible to
determine the specific functional impact of the
E
7/HIMEC
counterreceptor interaction.
The data presented herein demonstrate, for the first time, the presence
of another counterreceptor for the mucosal integrin
E
7 on nonepithelial
cells. This second
E
7
ligand may play a role in the selective recruitment of
E
7+
T cell subsets into the intestinal mucosa in combination with other
factors, or could transduce signals in either T cells or intestinal
endothelial cells. As an
anti-
E
7 mAb
ameliorates or abrogates intestinal inflammation in two murine models
(Ref. 58 and M.P. Schoen, J. Donohue, and C.M.P.,
unpublished data), agents that target the
E
7 interaction with
its ligands in the intestine may have efficacy in the treatment of
intestinal inflammation. Further studies will be required to define the
basic impact of the
E
7/HIMEC
counterreceptor interaction upon intestinal T cells homing and in the
functions of intestinal T cells and endothelial cells.
| Acknowledgments |
|---|
E
7 expressing JY'-
E cells,
the anti-E-cadherin mAb E4.6, the
E(D190A)
7-Fc, and for his ongoing
support; Marie Stockhausen for help with the culture of IEL lines; Dr.
David Erle (University of California, San Francisco, CA) for
E
7-transfected K562 cells; Drs. Michael
Briskin, Chafen Lu, and Dominic Picarella (Leukosite, Cambridge, MA)
for providing important reagents and for useful discussion; and Dr. Jay
Ponder (Washington University Medical School, St. Louis, MO) for advice
on linker construction within the
E
7-Fc
fusion protein encoding constructs. In addition, we want to thank
members of the Parker and Brenner Laboratories for helpful
discussions. | Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Christina M. Parker, Division of Rheumatology, Immunology, and Allergy, Brigham and Womens Hospital, Smith Building Room 552B, 1 Jimmy Fund Way, Boston, MA 02115. ![]()
3 Abbreviations used in this paper: iIEL, intestinal intraepithelial lymphocytes; MAdCAM-1, mucosal addressin cell adhesion molecule-1; HIMEC, human intestinal microvascular endothelial cells; HMVEC, human microvascular endothelial cells; MIDAS, metal ion-dependent adhesion site, VE-cadherin, vascular endothelial cadherin; E-cadherin, epithelial cadherin; HEK, human embryonic kidney; MFI, mean fluorescence intensity. ![]()
Received for publication June 21, 2000. Accepted for publication December 13, 2000.
| References |
|---|
|
|
|---|
4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions. J. Exp. Med. 192:495.
. Nature 361:79.[Medline]
7 integrins in formation of the gut-associated lymphoid tissue. Nature 382:366.[Medline]
4
7 on a subset of human CD4+ memory T cells with hallmarks of gut-trophism. J. Immunol. 151:717.[Abstract]
7 integrins and memory differentiation. J. Immunol. 156:3727.[Abstract]
7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue: [Published erratum appears in 1997 Immunology 91:322.]. Immunology 89:227.[Medline]
4
7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 74:185.[Medline]
4
7 (LPAM-1),
4
1 (VLA-4), and
IEL
7. Int. Immunol. 6:263.
4-integrins in lymphocyte homing to mucosal tissues in vivo. J. Immunol. 152:3282.[Abstract]
7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J. Immunol. 158:2099.[Abstract]
2 integrin (Mac-1) and L-selectin (LECAM-1) adherence receptors on human neutrophils by high-resolution field emission SEM. J. Histochem. Cytochem. 41:327.[Abstract]
4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 80:413.[Medline]
E
7 integrin. Eur. J. Immunol. 24:2832.[Medline]
E
7 mediates adhesion of T-lymphocytes to epithelial cells. J. Immunol. 150:3459.[Abstract]
E
7 integrin. Nature 372:190.[Medline]
M290
7(
E
7). Eur. J. Immunol. 25:852.[Medline]
E
7 with E-cadherin. J. Cell Biol. 140:197.
E
7 integrin in cutaneous T cell lymphoma. Am. J. Pathol. 145:1148.[Abstract]
E
7 integrin (CD103) and E-cadherin in epidermotropism in cutaneous T-cell lymphoma. J. Cutan. Pathol. 23:312.[Medline]
E
7-positive lymphocytes to oral and skin keratinocytes. Immunology 98:9.[Medline]